Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Guilhot J, et al. Among authors: saussele s. Blood. 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. Epub 2012 Apr 16. Blood. 2012. PMID: 22508936 Free article.
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R. Rohrbacher M, et al. Among authors: saussele s. Leukemia. 2009 Mar;23(3):602-4. doi: 10.1038/leu.2008.245. Epub 2008 Sep 11. Leukemia. 2009. PMID: 18784744 No abstract available.
The EUTOS CML score aims to support clinical decision-making.
Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Hoffmann V, et al. Among authors: saussele s. Blood. 2012 Mar 22;119(12):2966-7. doi: 10.1182/blood-2012-01-402511. Blood. 2012. PMID: 22442336 Free article. No abstract available.
Reply to H. Kantarjian et al.
Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Saußele S, Hochhaus A; Schweizer Arbeitsgemeinschaft für klinische; German CML-Study Group. Hehlmann R, et al. Among authors: saussele s. J Clin Oncol. 2014 Sep 20;32(27):3078-9. doi: 10.1200/JCO.2014.56.3908. J Clin Oncol. 2014. PMID: 25002729 No abstract available.
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Schütz C, et al. Among authors: saussele s. Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29381150
133 results